8-K: Century Therapeutics Transfers to Nasdaq Capital Market

Century Therapeutics, Inc. has transferred its listing to The Nasdaq Capital Market after failing to meet the $1.00 minimum bid price requirement for The Nasdaq Global Select Market.

Summary

• Century Therapeutics, Inc. received a deficiency letter on February 26, 2025, from Nasdaq for not meeting the $1.00 minimum bid price requirement (Rule 5450(a)(1)) for continued listing on The Nasdaq Global Select Market.
• The company did not regain compliance by the initial deadline of August 26, 2025.
• On August 27, 2025, Nasdaq granted an additional 180 calendar days, until February 23, 2026, to regain compliance.
• Nasdaq approved the company's transfer from The Nasdaq Global Select Market to The Nasdaq Capital Market, effective at the opening of business on August 27, 2025.
• The company's common stock continues to trade under the symbol IPSC on The Nasdaq Capital Market.
• The company intends to monitor its stock's closing bid price and will consider available options, including a reverse stock split, to regain compliance with the Bid Price Rule.

Sentiment

Score: 4

Explanation: The company failed to meet a key listing requirement and was transferred to a lower-tier market. While an extension was granted, and listing maintained, the underlying issue of low stock price and the potential for a reverse stock split are negative indicators.

Positives

• The company was granted an additional 180 calendar days, until February 23, 2026, to regain compliance with the minimum bid price rule.
• The company successfully transferred to The Nasdaq Capital Market, maintaining its listing on Nasdaq and avoiding immediate delisting.
• The company meets the continued listing requirement for market value of publicly held shares and all other initial listing requirements for The Nasdaq Capital Market, with the exception of the Bid Price Rule.

Negatives

• The company failed to meet The Nasdaq Global Select Market's $1.00 minimum bid price requirement by the initial August 26, 2025 deadline.
• The transfer from The Nasdaq Global Select Market to The Nasdaq Capital Market may be perceived as a downgrade in listing status.
• The potential need for a reverse stock split to regain compliance could be viewed negatively by investors.

Risks

• There is no assurance that the company will be able to regain compliance with the $1.00 minimum bid price rule by the Extended Compliance Date of February 23, 2026.
• The company may not be able to comply with other Nasdaq listing criteria in the future.
• Failure to regain compliance could lead to the company's common stock being delisted from Nasdaq.
• A reverse stock split, if implemented, carries risks including potential for further stock price decline or reduced liquidity.

Future Outlook

The company intends to continue monitoring the closing bid price of its common stock and will consider available options, including a reverse stock split, to regain compliance with the Bid Price Rule. There is no assurance that the company will be able to regain compliance or will otherwise be in compliance with other Nasdaq listing criteria.

Management Comments

• The company intends to continue to monitor the closing bid price of its common stock and will consider available options, including a reverse stock split, to regain compliance with the Bid Price Rule.

Industry Context

Companies, particularly smaller or emerging growth companies, often face challenges in maintaining minimum bid price requirements on major exchanges like Nasdaq, especially during periods of market volatility or when clinical development timelines are long. Transfers to the Nasdaq Capital Market are a common step to avoid delisting while working to regain compliance, allowing continued access to public markets.

Corporate Governance

Stakeholder Impact

• Shareholders: Face uncertainty regarding the company's ability to regain compliance, potential for a reverse stock split (which can lead to further price volatility or dilution perception), and continued trading on Nasdaq Capital Market.
• Investors: May view the transfer to Nasdaq Capital Market as a negative signal, potentially impacting investment decisions.

Next Steps

• Monitor the closing bid price of common stock.
• Consider available options, including a reverse stock split, to regain compliance with the Bid Price Rule.
• Regain compliance with the $1.00 minimum bid price rule by the Extended Compliance Date of February 23, 2026.

Key Dates

Recommendation

While the company failed to meet the initial Nasdaq minimum bid price requirement and was transferred to a lower-tier market, it has secured an extension to regain compliance and remains listed on Nasdaq. The situation presents significant uncertainty, including the potential for a reverse stock split and the risk of eventual delisting. Investors should hold to observe the company's progress in regaining compliance and the effectiveness of its strategies, such as a potential reverse stock split, before making further investment decisions.

Keywords

Century Therapeutics, IPSC, Nasdaq, Listing Compliance, Minimum Bid Price, Reverse Stock Split, Capital Market